Clinical Trials Browser

Approved for marketing × Prostatic Neoplasms × Clear all

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04809584 2024-12-19

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

Approved for marketing

Genitourinary

Prostatic Neoplasms

NCT04452136 2022-03-14

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

Approved for marketing

Genitourinary

Prostatic Diseases, Prostatic Neoplasms

NCT04348682 2021-06-24

Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging

Approved for marketing

Genitourinary

Prostatic Neoplasms

NCT04377152 2021-03-01

Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer

Approved for marketing

Genitourinary

Prostatic Neoplasms

NCT01217697 2017-03-24

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Approved for marketing

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT02355054 2017-01-20

Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study

Approved for marketing

Genitourinary

Prostatic Neoplasms, Recurrence